Compare AIIOW & ERNAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIIOW | ERNAW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United Arab Emirates | United States |
| Employees | 29 | 5 |
| Industry | Auto Manufacturing | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | AIIOW | ERNAW |
|---|---|---|
| Price | $0.06 | $0.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 335.3K | 81.3K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.01 | $0.02 |
| 52 Week High | $0.20 | $0.23 |
| Indicator | AIIOW | ERNAW |
|---|---|---|
| Relative Strength Index (RSI) | 54.11 | 56.09 |
| Support Level | $0.03 | $0.04 |
| Resistance Level | $0.15 | $0.23 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 35.23 | 54.55 |
Robo.ai Inc is a decentralized, AI-powered intelligent mobility platform that integrates smart vehicles, robotics, and blockchain technologies. The company is developing an AI-NAS ecosystem focused on delivering a passenger-centric platform by combining hardware and software, leveraging onboard computing, and offering an open cloud environment. Its product portfolio includes MUSE, a full-sized autonomous electric SPV; GHIATH, a purpose-built vehicle for public services and law enforcement developed in collaboration with Dubai Police; and Astra, an autonomous logistics vehicle. It also offers other vehicle models such as NWONE (SUV), Rabdan One (SUV), and Rabdan Seven (MPV) in the UAE through the SKD model. The company operates across the USA, UAE, and Mainland China.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.